Usher’s syndrome is a rare genetic condition that affects both hearing and vision, and sometimes balance, posing unique challenges that evolve throughout a person’s life. While there is currently no cure, advances in medical care and ongoing research offer hope for managing symptoms and improving quality of life for those living with this condition.

Understanding the Goals of Managing Usher’s Syndrome

When a person is diagnosed with Usher’s syndrome, the focus shifts to helping them live as fully and independently as possible despite the progressive nature of the condition. Treatment is not about curing the disease, but about preserving function, slowing decline, and supporting adaptation to changes in hearing and vision. The approach varies significantly depending on which type of Usher’s syndrome someone has, when symptoms appear, and how quickly they progress.^[1]

Medical professionals work with patients to create individualized plans that address hearing loss, vision problems, and balance difficulties. The earlier these interventions begin, the better the outcomes tend to be, particularly for children who are still developing language and learning skills. Early identification allows families to make informed decisions about communication methods, educational support, and assistive technologies that can make a meaningful difference in daily life.^[2]

There are established treatments approved by medical societies that have been used for decades to help people with Usher’s syndrome manage their symptoms. At the same time, scientists around the world are exploring innovative therapies through clinical trials, including gene therapy (a technique that aims to correct faulty genes), specialized drug treatments, and advanced technologies like retinal implants. These emerging approaches represent the cutting edge of research and may one day transform how Usher’s syndrome is treated.^[13][14]

Standard Treatment Approaches

Managing hearing loss in Usher’s syndrome typically begins with devices that amplify sound. Hearing aids are electronic devices worn in or behind the ear that make sounds louder, helping people with moderate hearing loss communicate more effectively. For individuals with severe or profound hearing loss, especially those with Type 1 Usher’s syndrome who are born deaf or nearly deaf, cochlear implants may be recommended. These are surgically placed devices that bypass damaged parts of the inner ear and directly stimulate the hearing nerve, allowing the brain to perceive sound signals.^[11][12]

The decision between hearing aids and cochlear implants depends on the degree of hearing loss and how well a person responds to amplification. Cochlear implants work best when placed early in childhood, particularly for Type 1 patients, because the developing brain is more adaptable to learning how to interpret the signals from the device. Many families also choose to teach their children American Sign Language alongside spoken communication, creating multiple pathways for connection with others throughout life.^[8]

For balance problems that occur particularly in Type 1 Usher’s syndrome, physical and occupational therapy play crucial roles. These therapies help strengthen core muscles and improve coordination. Orientation and mobility training teaches people how to navigate safely from one place to another, which becomes increasingly important as vision declines. This specialized instruction helps individuals maintain independence by learning techniques for traveling confidently in familiar and unfamiliar environments.^[11][17]

Vision support involves several complementary strategies. Low vision services provided by optometrists include training with optical and electronic magnification devices, techniques for using remaining vision more effectively, and environmental modifications such as improved lighting and enhanced contrast in the home. As vision declines, people may learn Braille, a tactile reading and writing system using raised dots, which allows continued access to written information even when sight is severely limited.^[11][12]

These standard interventions are ongoing rather than time-limited. A person with Usher’s syndrome may use hearing aids or cochlear implants throughout their entire life, upgrading technology as it improves. Vision services adapt as needs change, with different tools and strategies becoming relevant at different stages of vision loss. The goal is continuous support that evolves alongside the condition itself.^[2]

Innovative Therapies in Clinical Trials

The landscape of potential treatments for Usher’s syndrome has expanded dramatically in recent years as researchers have identified the specific genetic mutations responsible for different types of the condition. This knowledge has opened the door to therapies that target the underlying causes rather than just managing symptoms. While none of these experimental treatments are yet approved for general use, they represent promising directions that may fundamentally change the future of Usher’s syndrome care.^[14]

Gene therapy represents one of the most exciting frontiers in Usher’s syndrome research. This approach involves delivering correct copies of faulty genes directly to cells in the retina or inner ear. For Usher syndrome Type 1B, caused by mutations in the MYO7A gene, AAVantgarde Bio has initiated a Phase 1/2 clinical trial using a dual-vector gene therapy approach. The trial, called LUCE-1, is taking place at the University Hospital of Campania in Naples, Italy, with additional sites planned in the United Kingdom. This represents the first-in-human testing of this specific gene therapy strategy.^[13]

Phase 1/2 trials are early-stage studies that primarily assess safety while also beginning to gather information about whether the treatment shows any beneficial effects. Participants in these trials are carefully monitored for any adverse reactions, and researchers measure whether the therapy reaches its target tissues and produces the intended biological changes. These trials typically involve small numbers of participants and provide crucial data that guides decisions about whether to proceed to larger studies.^[14]

Another promising avenue involves antisense oligonucleotide therapies, which are specialized molecules that can modify how genes are expressed. Sepul Bio, a new business unit of Théa, is advancing two such treatments through clinical trials. One is called ultevursen, designed for people with Usher syndrome Type 2A who have specific mutations (exon 13 mutations) in the USH2A gene. This therapy is being studied in a Phase 2b trial called LUNA. The other is sepofarsen, for people with Leber congenital amaurosis Type 10 caused by a particular mutation in the CEP290 gene, which is being tested in a Phase 3 trial called HYPERION. Both of these RNA-based therapies had shown promising results in earlier clinical studies.^[13]

Phase 2 trials are designed to determine whether a treatment has beneficial effects and to identify the optimal dose. Phase 3 trials are larger studies that compare the new treatment to current standard care or placebo to definitively establish whether the therapy should be approved for widespread use. The fact that these trials are progressing through these stages suggests the treatments have demonstrated acceptable safety profiles and enough preliminary effectiveness to warrant continued investigation.^[14]

An oral antioxidant medication called NACA (N-acetylcysteine-amide) is being studied for its potential to protect retinal cells from damage. Nacuity, a Dallas-based company, reported that in a Phase 2 clinical trial conducted in Australia for people with Usher syndrome, NACA reduced photoreceptor cell loss by 50 percent. Photoreceptors are the cells in the retina that capture light and begin the process of vision. The Foundation Fighting Blindness has invested up to $7.5 million to advance this drug for retinitis pigmentosa, Usher syndrome, and related conditions. The mechanism of NACA involves reducing oxidative stress, a harmful process where unstable molecules damage cells. By providing antioxidant protection, NACA may slow the gradual death of photoreceptor cells that causes progressive vision loss.^[13]

For some types of Usher syndrome, researchers are exploring drugs that can overcome specific types of genetic mutations. A medication called Ataluren (originally known as PTC 124) has been developed to address nonsense mutations, a particular kind of genetic error where the instructions for making a protein are cut off prematurely. While this drug has been tested primarily in other genetic diseases like Duchenne muscular dystrophy and cystic fibrosis, researchers in Germany have been evaluating it in mouse models of Usher syndrome Type 1C. A similar approach involves modified antibiotics called aminoglycosides, with researchers at the Technion in Israel developing a modified version called NB54 specifically designed to be safe for long-term human use in treating Usher syndrome Type 1F, which is relatively common among Ashkenazi Jewish populations.^[14]

Beyond medications and gene therapies, researchers are developing retinal implants that function somewhat like cochlear implants for the eye. The Argus artificial retina system, funded by the U.S. Department of Energy, has progressed from 16-electrode to 60-electrode versions (Argus I and II) in clinical trials, with even more advanced versions in development. These devices use a small camera mounted on glasses that sends signals to an electrode array implanted on the retina, bypassing damaged photoreceptor cells to stimulate remaining nerve cells directly. Similarly, researchers at the Massachusetts Institute of Technology are developing an implant system with electrodes attached to the retina and the main chip implanted outside the eye. Clinical trials for this approach are expected to begin within a few years.^[14]

The journey of a therapy from laboratory research to approved treatment typically takes many years. Even treatments now in Phase 2 or Phase 3 trials may require several more years of study and regulatory review before becoming available to patients outside of research settings. Scientists must demonstrate not only that treatments work, but that they work safely across diverse populations and that their benefits outweigh any risks. This rigorous process protects patients while ensuring that new therapies represent genuine advances in care.^[14]

Most Common Treatment Methods

• Hearing Management
  • Hearing aids amplify sound for people with moderate hearing loss, helping them communicate more effectively in daily life
  • Cochlear implants are surgically placed devices that directly stimulate the hearing nerve, particularly beneficial for profound hearing loss in Type 1 Usher’s syndrome
  • American Sign Language provides an alternative communication method that remains effective even as hearing declines
  • Assistive listening devices enhance sound in specific situations like classrooms or meetings
• Vision Support Services
  • Low vision services include training with magnification devices, techniques for using remaining vision efficiently, and environmental modifications
  • Braille instruction provides access to reading and writing through a tactile system of raised dots
  • Orientation and mobility training teaches safe and independent navigation skills as vision declines
  • Protective eyewear including sunglasses helps shield eyes from potentially damaging ultraviolet light
  • Vitamin A supplementation at 15,000 IU daily may slow retinitis pigmentosa progression in some adult patients under medical supervision
• Balance and Mobility Interventions
  • Physical therapy strengthens core muscles and improves coordination, particularly important for Type 1 patients with vestibular dysfunction
  • Occupational therapy helps develop strategies for daily activities and maintaining independence
  • Mobility aids and environmental modifications improve safety in home and community settings
• Experimental Therapies in Clinical Trials
  • Gene therapy approaches for Type 1B (MYO7A mutations) delivering correct gene copies to retinal cells in Phase 1/2 trials
  • Antisense oligonucleotide therapies (ultevursen for USH2A mutations, sepofarsen for CEP290 mutations) modifying gene expression in Phase 2b and Phase 3 trials
  • Oral antioxidant NACA reducing photoreceptor cell loss through protection from oxidative stress in Phase 2 trials
  • Medications targeting specific mutation types like Ataluren for nonsense mutations and modified aminoglycosides like NB54 in laboratory and early testing phases
  • Retinal implant systems (Argus II and others) using camera-and-electrode technology to bypass damaged photoreceptors and stimulate retinal nerves directly